Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YYB101 + irinotecan
- Development stage
- Unknown
- Lead developer
- CellabMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**YYB101 + irinotecan** is an experimental combination therapy consisting of YYB101, a humanized monoclonal antibody targeting hepatocyte growth factor (HGF), and irinotecan, a topoisomerase I inhibitor. YYB101 blocks the HGF/MET signaling pathway, inhibiting tumor growth, migration, and infiltration by binding to the alpha chain of HGF, thereby preventing its interaction with the MET receptor[1][5]. Irinotecan interferes with DNA replication by inhibiting DNA topoisomerase I, resulting in DNA strand breaks and cell death[2][4]. This combination is being investigated for the treatment of refractory/metastatic solid tumors, notably metastatic colorectal cancer[1].
- Other names
- irinotecanYYB101YYB-101YYB 101
02
Targets
HGF (Hepatocyte growth factor)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on YYB101 + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YYB101 + irinotecan.